EyeGate Pharmaceuticals reported a net loss of $4.1 million in the third quarter of 2017 compared with a net loss of $3.4 million in the same time period of 2016.
Revenues were down from $0.274 million in 2016’s third quarter to $0.075 million in the third quarter of 2017, according to a press release.
Research and development costs rose to $3.2 million in the quarter from $2.5 million in 2016’s third quarter, while general and administrative costs were down to $1 million from $1.2 million.
The company reported cash and cash equivalents of $9.2 million as of Sept. 30.
Month: November 2017
Body Monitoring Sensors from Shimmer Help Researchers Get Science Done
The Med in Ireland conference that we recently had a chance to visit, featured Shimmer, a successful body-sensing firm out of Dublin. The company also has offices in Cambridge, MA and Kuala Lumpur, Malaysia. They build a variety of modular sensing devices for clinical studies, product development, and anything else that would require to record […]
Machine Learning and Computer Simulations to Help Detect Effects of Drugs on Brain
Researchers at University College London are attempting to combine knowledge and models about the brain with clinical trial data, with the ultimate goal of discovering new drug therapies that would otherwise be undetected. The researchers hope to use machine learning techniques that can process lots of data to find correlations that can be spotted in […]
A Shared Vision to Improve Clinical Trial Technology: Interview with Bracket’s Adam Butler on mProve Health Acquisition
Last month, Bracket, a clinical trial technology and specialty service provider, shared the announcement that it had acquired mProve Health, a mobile technology company whose offerings include an Electronic Patient-Reported Outcomes (ePRO) platform. The news represented a compelling success story amidst recent pessimism regarding the digital health sector. Following up with Bracket after the announcement, Medgadget was able to […]
Tiny Medicare Raise Gets Tinier, Again
An annual 0.5% rate hike promised by MACRA wasn’t much to begin with. Physicians haven’t received it for 3 straight years, owing to Medicare math. Medscape Medical News
Glued intrascleral haptic fixation yields fewer complications than transscleral suturing
Intrascleral haptic fixation with fibrin glue provides less traumatic and more stable IOL positioning that sutured scleral fixation, leading to better visual outcomes and fewer complications, according to a study.The comparison was made in a tertiary c…
APAO LDP holds mid-year master class
The 2017-2018 Class of the Asia-Pacific Academy of Ophthalmology Leadership Development Program met for its mid-year master class in Colombo, Sri Lanka, during the annual meeting of the College of Ophthalmologists of Sri Lanka, or COSL, from Sept. 29 t…
IOPtima acquired by Chengdu Kanghong Pharmaceutical Group
Chengdu Kanghong Pharmaceutical Group, a China-based company, purchased IOPtima, according to a press release.
A $7 million investment into IOPtima began the four-stage transaction, which will continue with Chengdu Kanghong gradually acquiring all of the company’s shares by 2021. Chengdu Kanghong will also be IOPtima’s distributor in China.
IOPtima manufactures the IOPtiMate system for surgically treating glaucoma and is developing laser products and accessories for glaucoma and other ophthalmic diseases. The main ophthalmic product from Chengdu Kanghong is conbercept for wet
RightEye Partners with Tobii on New Eye-Tracking System for Vision Tests
WASHINGTON–(BUSINESS WIRE)–RightEye LLC, a leading health innovator that uses eye-tracking technology to revolutionize patient care and vision performance, announced today it has signed an agreement with Tobii, the world leader in eye-tracking technology. Through the collaboration, the companies will co-develop new hardware solutions to complement RightEye vision tests and training games for customers in vision, health care and sports markets. “We’re excited to be partnering with Tobii to adv
VIDEO: Single-pass four-throw pupilloplasty effective in Urrets-Zavalia syndrome
NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Priya Narang, MS, discusses how the single-pass four-throw pupilloplasty technique can be effective in cases of Urrets-Zavalia syndrome.
Meet Versius, Cambridge Medical Robotics’ More Portable and Cost Effective Robot for Minimal Access Surgery
Cambridge Medical Robotics (CMR), based in the UK, is working on revolutionizing the world of surgery by delivering what the firm believes is the next generation surgical robot. More versatile, affordable, and easier to use than other robots on the market, CMR’s Versius system is already generating significant interest. The company announced in September that […]
Ocular Drug Delivery Implant Treats Glaucoma From Inside the Eye
Glaucoma is an eye disease that can damage the optic nerve and lead to irreversible vision loss. It affects an estimated 60 million people around the world, but is one of the most easily treatable diseases, typically only requiring medicated drops. Unfortunately, prescription eye drops are one of the most difficult drug delivery methods to […]
Ultrathin and Flexible Microfiber Sensor for Healthcare Monitoring and Diagnosis
Researchers at the National University of Singapore have developed an ultrathin, flexible microfiber sensor that can be worn on or placed next to the skin. The device can provide information on heart rate, blood pressure, and stiffness in blood vessels, and may one day replace bulky blood pressure and heart rate monitors. The technology might […]
Ophthotech net income reaches $189.1 million in third quarter
Ophthotech reported a net income of $189.1 million, or $5.25 per diluted share, in the third quarter of 2017 compared with a net loss of $60.9 million, or $1.71 per diluted share, in the same quarter of last year.
Quarterly collaboration revenue was $206.7 million compared with $1.7 million in the same period a year ago. The increase was attributed to Ophthotech completing “all deliverables required under its licensing and commercialization agreement with Novartis Pharma AG” and recognizing associated deferred revenue, according to a press release.
General and administrative
Guided Microrobots Made of Algae and Magnetic Particles
Researchers have developed microrobots using algae and magnetic particles that can be guided magnetically to sites in the body and tracked, by spotting the algae’s natural luminescence or using an MRI scanner. The investigators hope that swarms of these tiny robots could help with diagnostics and treatment in areas of the body that are currently […]
Ingestible Biosensor for Tracking Opioid Use Following Acute Injury
Opioids, such as oxycodone, are routinely prescribed for short-term pain management following pain-inducing injuries. However, their use is associated with the development of tolerance and addiction, due in part to dosage mismanagement by patients. Recently, the FDA approved the use of the first digital pill administered in combination with a prescription drug. Digital pills, which […]
Ozurdex limits number of treatments needed in real-life DME
Ozurdex was found to be safe and effective for the treatment of diabetic macular edema in a real-life, prospective study.The study included 54 eyes of 54 patients with DME refractory to previous treatment with anti-VEGFs. Ozurdex (dexamethasone intravi…
Digital image of the retina provides enormous information about patients’ general health
Personalized medicine or “precision medicine” is the most significant trend in 21st century medicine. “It’s all about the right treatment for the right patient at the right time,” says Ursula Schmidt-Erfurth, Head of MedUni Vienna’s Department of Ophth…
VIDEO: Study finds most adjunctive glaucoma therapies used only twice a day
NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Savak “Sev” Teymoorian, MD, MBA, discusses a survey of adjunctive glaucoma therapy prescribing by ophthalmologists that shows the majority prescribe twice a day as opposed to the labeled three times daily treatment. The study found adherence and patient quality of life were the main factors.
Ambry Genetics’ Mitochondrial Disease Research May Help Develop Treatments Sooner
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ambry Genetics Corporation (Ambry), a leading clinical genetics-testing lab, recently published a paper concerning mutations in the FDXR gene, detailing how a team of researchers completed an entire diagnostic journey – from novel gene identification to potential treatment development; offering hope of a treatment to patients with vision loss due to mitochondrial disease. The paper, Biallelic mutations in the ferredoxin reductase gene cause novel mitochondr